Arcutis Biotherapeutics(ARQT.US) Director Sells US$93,141 in Common Stock

$Arcutis Biotherapeutics(ARQT.US)$ Director Welgus Howard G. sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $9.3141 for a total value of $93,141.Source: Announcement What is

Moomoo News19:53 ET

Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals

New York, USA, July 02, 2024 (GLOBE NEWSWIRE) -- Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant

GlobeNewswire13:00 ET

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

Yahoo FinanceJun 26 12:57 ET

Arcutis Biotherapeutics Insiders Sold US$619k Of Shares Suggesting Hesitancy

A number of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insiders sold their shares in the last year, which may have raised concerns among investors. When evaluating insider transactions, knowing whe

Simply Wall StJun 21 06:27 ET

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell sharply in today's pre-market trading

BenzingaJun 20 05:29 ET

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Yahoo FinanceJun 17 09:40 ET